Sequentially Regulated Lysosomal Assembly Formation and Degradation for Potent Inflammasome Driven Immunotherapy
Small · 2025
DOI: 10.1002/smll.202506341 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Runxiao Zheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Science and Technology Innovation Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 2500…. Hauptthemen laut MEDLINE: Lysosomes, Inflammasomes, Immunotherapy. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Traditional Chinese Medicine Science and Technology Project of Shandong Province, Project for Scientific Research Innovation Team of Young Scholars in Colleges and Universities of Shandong Province.
Abstract (Originalsprache)
Inflammasome‐mediated in situ cancer vaccines hold promise for cancer immunotherapy but are hampered by poor specificity to the tumor microenvironment (TME) and inadequate antigen‐specific immune responses. Here, sequentially regulated transmutable nanoparticles ( PEG CSMP NPs) are developed to enhance NLRP3 inflammasome activity and induce chemodynamic therapy (CDT) for robust adjuvant and antigens effects. Copper–manganese silicate nanoparticles (CSM NPs) are functionalized with molybdenum polyoxometalate (POM) clusters and ROS‐cleavable poly(ethylene glycol) (mPEG) to form PEG CSMP NPs. Upon exposure to high ROS levels in the TME, PEG CSMP NPs shed their PEG layer, triggering aggregation and lysosomal rupture in dendritic cells (DCs) to activate the NLRP3 inflammasome. Meanwhile, high glutathione (GSH) levels in tumor cells degrade the aggregated particles, releasing metal ions that induce CDT to damage tumor cells and release tumor‐associated antigens (TAAs). This dual mechanism of lysosomal assembly formation and degradation enhances antigen presentation and T cell activation for precise cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Science and Technology Innovation Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.
- Laboratory of Chemical Biology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun, Jilin, 130022, China.
- School of Biomedical Engineering & The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510120, China.
- The Institute of Physical Organic Chemistry of the National Academy of Sciences of Belarus, Minsk, 220072, Belarus.
- State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China.
ORCID-Profile: Runxiao Zheng, Haiyuan Zhang
Förderung
- National Natural Science Foundation of China
- Traditional Chinese Medicine Science and Technology Project of Shandong Province
- Project for Scientific Research Innovation Team of Young Scholars in Colleges and Universities of Shandong Province
- Natural Science Foundation of Shandong Province
- Taishan Scholar Foundation of Shandong Province
Zitieren
APA
Zheng, R., Li, C., Huang, C., He, Q., Wang, Y., Song, P., Shmanai, V. V., Xia, M., Jiao, J., & Zhang, H. (2025). Sequentially Regulated Lysosomal Assembly Formation and Degradation for Potent Inflammasome Driven Immunotherapy. Small. https://doi.org/10.1002/smll.202506341
Vancouver
Zheng R, Li C, Huang C, He Q, Wang Y, Song P, et al. Sequentially Regulated Lysosomal Assembly Formation and Degradation for Potent Inflammasome Driven Immunotherapy. Small. 2025. doi:10.1002/smll.202506341
BibTeX
@article{Zheng2025,
author = {Zheng, Runxiao and Li, Chengzhilin and Huang, Changshun and He, Qingbin and Wang, Yanjing and Song, Panpan and Shmanai, Vadim V and Xia, Ming and Jiao, Jianwei and Zhang, Haiyuan},
title = {Sequentially Regulated Lysosomal Assembly Formation and Degradation for Potent Inflammasome Driven Immunotherapy},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202506341}
}
EUVIMED